Jubilant Therapeutics Inc. is advancing precision therapies, with its dual inhibitor JBI-802 showing activity in myeloproliferative neoplasms.
1 report, 1 independent
Updated Sep 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jubilant Therapeutics Inc. is advancing precision therapies, with its dual inhibitor JBI-802 showing activity in myeloproliferative neoplasms.